Swedish company Recipharm, a leading global pharmaceutical Contract Development and Manufacturing Organisation (CDMO) has joined the consortium of the Mohammed VI Fund for Investment, three major national banking groups including Banque Centrale Populaire, Bank of Africa, and Attijariwafa Bank, and Samir Machour, Senior Vice President and Chief Quality Officer at Samsung Biologics, South Korea, to establish Senso Pharmatech SA, a vaccine manufacturing unit in Benslimane, Morocco. The project, on completion, will be the largest manufacturing and packaging unit of vaccines, including COVID-19 vaccines for the entire African continent.
The Benslimane project aims to establish a factory for the manufacture and packaging of vaccines (COVID-19 and other vaccines), containing three industrial lines with a joint capacity to produce 116 million units by the year 2024. These lines will be dedicated to the production of pre-filled syringes, vials of liquids, and other freeze-dried ones. The expected investment is about 200 million Euros, with the production of trial packages to be launched on July 30, 2022.
The project aspires to create a globally recognized African pole of biopharmaceutical and vaccine innovation in Morocco in the fields of research and development of advanced technologies in vaccine and bio-therapeutic products, involving the ministries of higher education and health, the interior, and industry and finance.
A broad and continuous transfer of expertise will be carried out with the aim of making Morocco a locomotive for the African continent in the field of research, development, and production of advanced bio-pharmaceutical products.
